Financial Survey: Dogwood Therapeutics (NASDAQ:DWTX) versus Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech (NASDAQ:MBRX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional and Insider Ownership

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 3.4% of Moleculin Biotech shares are held by company insiders. Comparatively, 3.6% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Moleculin Biotech and Dogwood Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	-1,498.41%	-114.47%
Dogwood Therapeutics	N/A	N/A	-34.74%

Analyst Ratings

This is a summary of recent ratings for Moleculin Biotech and Dogwood Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1	0	2	0	2.33
Dogwood Therapeutics	1	0	1	0	2.00

Moleculin Biotech currently has a consensus target price of $4.00, suggesting a potential upside of 718.00%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 128.14%. Given Moleculin Biotech’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Moleculin Biotech is more favorable than Dogwood Therapeutics.

Volatility and Risk

Moleculin Biotech has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.

Earnings and Valuation

This table compares Moleculin Biotech and Dogwood Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$21.76 million	($3.27)	-0.15
Dogwood Therapeutics	N/A	N/A	-$12.35 million	($24.93)	-0.21

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Moleculin Biotech beats Dogwood Therapeutics on 6 of the 11 factors compared between the two stocks.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.